09955 CLOUDR
- 2.940
- +0.100+3.52%
CLOUDR News
智雲健康：年報2023
Hong Kong stock changes丨Zhiyun Health rose more than 9% to launch the first digital employee “A Word Like a Jade - Xiaoyu”
Glonghui, April 24 | Zhiyun Health (9955.HK) rose 9.47% to HK$2.66, with a turnover of HK$504.962 million and a total market value of HK$1,562 billion. Recently, Zhiyun Health's first digital employee, “A Word Like Jade - Xiaoyu”, was officially launched to improve the operational efficiency of out-of-hospital solutions. According to reports, the digital employee intelligently operates products based on a large model, and has the ability to understand text, answer questions, and analyze emotions. It can perform various functions such as intelligent response and operation support, release productivity, help retail pharmacies improve operational efficiency, and achieve revenue and cost reduction.
ClouDr Launches Digital Employee to Improve Online-to-Offline Operation Services
ClouDr Group (HKG:9955) recently launched its first digital employee, Yan Ruyu — Xiaoyu, to optimize and upgrade the workflow and operation mode of its online-to-offline (O2O) operation services. The
Zhiyun Health (09955) launches the first digital employee to help improve the efficiency of out-of-hospital solutions
Zhiyun Health (09955) announced that recently, as a leader in digitally empowering pharmacy operations, the company recently launched...
Changes in Hong Kong stocks | Zhiyun Health (09955.HK) reached a high of nearly 13%, and the company's revenue continues to grow, P2M strategy opens up profit space
Zhiyun Health (09955.HK) reached a high of nearly 13%. As of press release, it rose 8.82% to HK$2.96, with a turnover of HK$56.5093 million.
HK stock changes丨Zhiyun Health boosted more than 18%
Glonghui, April 11 | Zhiyun Health (9955.HK) showed a clear upward trend in the afternoon. At one point, it rose more than 18% to HK$2.86 in the intraday period, and the turnover increased to over HK$52 million. The company's results previously announced on March 21 showed that revenue in 2023 maintained a rapid growth trend, with operating revenue rising 23.5% year-on-year to 3.69 billion yuan. Among them, in-hospital solution revenue was 2.87 billion yuan, accounting for more than 70%, the largest revenue source, up 31.5% year on year; pharmacy solution revenue was 660 million yuan, up 6.9% year on year; personal chronic disease management solutions and other revenue
Zhiyun Health (09955): Unusual share price and trading volume fluctuations The management team is still confident about the company's long-term prospects
Zhitong Finance App News, Zhiyun Health (09955) announced that the company's shares have recently experienced a drop in transaction price and an increase in trading volume. After making all reasonable enquiries about the Company's circumstances, the Board confirmed that it was unaware of any reason for the recent fluctuations in transaction prices and volume, or any information that must be published to avoid causing a false market in the Company's securities, or any insider information required to be disclosed in accordance with Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). The board of directors confirmed that the company's business operations are in good condition and that the management team has maintained a long-term relationship with the company
Zhiyun Health (09955.HK): Loss reduction exceeds expectations, exploring a new P2M model
Revenue for 2023 fell short of our expectations, and the loss margin was less than our expectations, Zhiyun Health announced 2023 results: Revenue increased 23.5% year-on-year to 3.69 billion yuan, lower than our previous expectations, mainly due to quasi-marketing and pharmacy solutions
Changes in Hong Kong stocks | Zhiyun Health (09955) rose more than 7% in 23 years, the company's revenue maintained rapid growth and turned a loss into a profit in the fourth quarter
The Zhitong Finance App learned that Zhiyun Health (09955) rose by more than 7% and rose 7.19% at press time to HK$3.13, with a turnover of HK$21.77 million. According to the news, on March 21, financial reports showed that in 2023, Zhiyun Health's revenue continued to grow rapidly, with revenue reaching 3.69 billion yuan, an increase of 23.5% over the previous year. Non-IFRS (non-IFRS) adjusted net loss narrowed to 75.1 million yuan, a year-on-year decrease of 77.4%. The fourth quarter became the company's first profitable quarter, turning losses into profits in a single quarter. Financial reports show that Zhiyun Health's three major business boards
ClouDr Group's Net Loss Shrinks 81% in 2023 as Revenue Rises 23.5%
ClouDr Group (HKG:9955) narrowed its net loss by 80.7% to 327.34 million yuan in the year ended Dec. 31, 2023, against 1.69 billion yuan a year ago, according to a Thursday filing with the Hong Kong S
Zhiyun Health (09955) Digitalization empowers pharmacy operations to improve quality and efficiency
More than 200,000 pharmacies across the country have installed the Zhiyun Health Pharmacy SaaS system. The Zhiyun Health Out-of-Hospital platform links upstream and downstream partners outside the hospital, carries services and products, and relies on a strong central platform to support the efficient operation of out-of-hospital business.
The rapid development of “Internet+Healthcare” Zhiyun Health (09955)'s revenue in 2023 increased 23.5% year-on-year to 3.69 billion yuan
Zhiyun Health (09955) announced its annual results for the year ended December 31, 2023, with group revenue of RMB 36...
A Sino-German business exchange meeting was held in Beijing. Zhiyun Health (09955) explores new opportunities for international cooperation
The Zhitong Finance App learned that on March 18, the China Small and Medium Enterprises International Cooperation Association and the German Federal Federation of Small and Medium Enterprises held a bilateral exchange meeting in Beijing. Shao Ning, Chairman of the China SME International Cooperation Association, Dr. Jochen Leonhardt, Chairman of the Board of the German SME Federation, Shan Lipo, Vice President and Secretary General of the China SME International Cooperation Association and Director of the China SME Development Promotion Center, representatives of Chinese enterprises, and representatives of German enterprises gathered to have friendly exchanges and discuss opportunities for cooperation on the macro environment, development status and work direction of SME international cooperation. Zhiyun Health (09955) Vice
Understand the 2023 annual results of Zhiyun Health (09955.HK) in one picture
On March 21, Zhiyun Health (09955.HK) officially announced the 2023 performance report. Let me take you to understand the specific results in a picture.
Zhiyun Health announced its 2023 results: a sharp decrease of about 260 million dollars for the whole year, narrowing by 77.4% year-on-year, and turning losses into profits in the fourth quarter
GLONGHUI March 21 | Zhiyun Health (9955.HK) officially announced the 2023 performance report. The report shows that in 2023, Zhiyun Health's revenue continued to grow rapidly, with revenue reaching 3.69 billion yuan, an increase of 23.5% over the previous year. Among them, in-hospital solution revenue was 2.87 billion yuan, accounting for more than 70%, the largest revenue source, up 31.5% year on year; pharmacy solution revenue was 660 million yuan, up 6.9% year on year; and personal chronic disease management solutions and other revenue was 160 million yuan. Non-IFRS (Non-IFRS) adjusted net loss narrowed to
CLOUDR: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023
Zhiyun Health (09955.HK) plans to hold a board meeting on March 21 to approve annual results
Gelonghui, March 11, 丨 Zhiyun Health (09955.HK) issued an announcement. The board of directors hereby announces that a board meeting will be held on March 21, 2024 (Thursday) to consider and approve the annual results of the company and its subsidiaries for the year ended 31 December 2023 and to deal with other matters.
CLOUDR: DATE OF BOARD MEETING
ClouDr Launches Diabetes Tablets; Shares Up 3%
ClouDr (HKG:9955) launched its Hetangjin-branded dapagliflozin tablets for type 2 diabetes, according to a Monday filing with the Hong Kong bourse. China's medical products administrator approved the
Hong Kong stock changes丨Zhiyun Health opened 5.65%, and the blood sugar control drug “Hetang Jing” entered the marketing and sales stage
Gelonghui March 11 | Zhiyun Health (9955.HK) opened 5.65% higher at HK$4.3. According to the news, the company announced that the launch meeting for the Group's proprietary product “Hetangjing” dagliflozin tablets will be held on March 9, marking that the product has entered the marketing and sales stage after officially obtaining the drug registration certificate (Sinopharm license H20234636) issued by the State Drug Administration on December 13, 2023.
Analysis
Price Target
No Data
